These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 22661496)

  • 1. Improving drug delivery to pancreatic cancer: breaching the stromal fortress by targeting hyaluronic acid.
    Michl P; Gress TM
    Gut; 2012 Oct; 61(10):1377-9. PubMed ID: 22661496
    [No Abstract]   [Full Text] [Related]  

  • 2. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer.
    Jacobetz MA; Chan DS; Neesse A; Bapiro TE; Cook N; Frese KK; Feig C; Nakagawa T; Caldwell ME; Zecchini HI; Lolkema MP; Jiang P; Kultti A; Thompson CB; Maneval DC; Jodrell DI; Frost GI; Shepard HM; Skepper JN; Tuveson DA
    Gut; 2013 Jan; 62(1):112-20. PubMed ID: 22466618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer. Breaching the cancer fortress.
    Olson P; Hanahan D
    Science; 2009 Jun; 324(5933):1400-1. PubMed ID: 19520948
    [No Abstract]   [Full Text] [Related]  

  • 4. Can intracellular drug delivery using hyaluronic acid functionalised pH-sensitive liposomes overcome gemcitabine resistance in pancreatic cancer?
    Tang M; Svirskis D; Leung E; Kanamala M; Wang H; Wu Z
    J Control Release; 2019 Jul; 305():89-100. PubMed ID: 31096017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma.
    Provenzano PP; Cuevas C; Chang AE; Goel VK; Von Hoff DD; Hingorani SR
    Cancer Cell; 2012 Mar; 21(3):418-29. PubMed ID: 22439937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gemcitabine: metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer.
    de Sousa Cavalcante L; Monteiro G
    Eur J Pharmacol; 2014 Oct; 741():8-16. PubMed ID: 25084222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting cMET with INC280 impairs tumour growth and improves efficacy of gemcitabine in a pancreatic cancer model.
    Brandes F; Schmidt K; Wagner C; Redekopf J; Schlitt HJ; Geissler EK; Lang SA
    BMC Cancer; 2015 Feb; 15():71. PubMed ID: 25884642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ultrasound and microbubble enhanced treatment of inoperable pancreatic cancer.
    Park K
    J Control Release; 2016 Dec; 243():381. PubMed ID: 28024837
    [No Abstract]   [Full Text] [Related]  

  • 9. HALO-109-301: a Phase III trial of PEGPH20 (with gemcitabine and nab-paclitaxel) in hyaluronic acid-high stage IV pancreatic cancer.
    Doherty GJ; Tempero M; Corrie PG
    Future Oncol; 2018 Jan; 14(1):13-22. PubMed ID: 29235360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploring protein kinase inhibitors: unveiling gemcitabine resistance in pancreatic cancer.
    Kim YJ; Hong YB; Cho CH; Seong YS; Bae I
    Pancreas; 2012 Jul; 41(5):804-5. PubMed ID: 22695089
    [No Abstract]   [Full Text] [Related]  

  • 11. Gemcitabine resistance in pancreatic cancer: picking the key players.
    Kim MP; Gallick GE
    Clin Cancer Res; 2008 Mar; 14(5):1284-5. PubMed ID: 18316544
    [No Abstract]   [Full Text] [Related]  

  • 12. [Gemcitabine chemotherapy for patients with advanced or relapsed pancreatic cancer].
    Ohkawa S
    Nihon Rinsho; 2006 Jan; 64 Suppl 1():198-202. PubMed ID: 16457249
    [No Abstract]   [Full Text] [Related]  

  • 13. Notch1 contributes to chemoresistance to gemcitabine and serves as an unfavorable prognostic indicator in pancreatic cancer.
    Du X; Zhao YP; Zhang TP; Zhou L; Chen G; Cui QC; Shi J; Wang TX; You L; Shu H
    World J Surg; 2013 Jul; 37(7):1688-94. PubMed ID: 23568245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma.
    Hingorani SR; Zheng L; Bullock AJ; Seery TE; Harris WP; Sigal DS; Braiteh F; Ritch PS; Zalupski MM; Bahary N; Oberstein PE; Wang-Gillam A; Wu W; Chondros D; Jiang P; Khelifa S; Pu J; Aldrich C; Hendifar AE
    J Clin Oncol; 2018 Feb; 36(4):359-366. PubMed ID: 29232172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ultrasound and microbubble assisted drug delivery - A clinical pharmacological perspective.
    Bjånes TK; Riedel B; Schjøtt J
    Pharmacol Res; 2021 Mar; 165():105475. PubMed ID: 33524538
    [No Abstract]   [Full Text] [Related]  

  • 16. EGFR-targeted gelatin nanoparticles for systemic administration of gemcitabine in an orthotopic pancreatic cancer model.
    Singh A; Xu J; Mattheolabakis G; Amiji M
    Nanomedicine; 2016 Apr; 12(3):589-600. PubMed ID: 26656632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Options for the treatment of gemcitabine-resistant advanced pancreatic cancer: are we there yet?
    Saif MW
    JOP; 2010 May; 11(3):288-9; author reply 290. PubMed ID: 20442533
    [No Abstract]   [Full Text] [Related]  

  • 18. pH-Sensitive Nanoparticles Composed Solely of Membrane-Disruptive Macromolecules for Treating Pancreatic Cancer.
    Fan F; Jin L; Yang L
    ACS Appl Mater Interfaces; 2021 Mar; 13(11):12824-12835. PubMed ID: 33689289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peptide-functionalized nanoparticles for selective targeting of pancreatic tumor.
    Valetti S; Maione F; Mura S; Stella B; Desmaële D; Noiray M; Vergnaud J; Vauthier C; Cattel L; Giraudo E; Couvreur P
    J Control Release; 2014 Oct; 192():29-39. PubMed ID: 24984010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gemcitabine doublets in advanced pancreatic cancer: should we move on?
    Rocha Lima CM; Flores AM
    J Clin Oncol; 2006 Jan; 24(3):327-9. PubMed ID: 16344312
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.